Related Experiment Video
Updated: Aug 16, 2026
The Establishment of a Lung Colonization Assay for Circulating Tumor Cell Visualization in Lung Tissues
Published on: June 16, 2018
[Matrix metalloproteinases and their inhibitors in lung cancer with malignant pleural effusion]
1Medizinische Klinik und Poliklinik I, Abteilung Pneumologie, Universität Leipzig.
Unlabelled:
Matrix metalloproteinases (MMP) and tissue inhibitors of metalloproteinases (TIMP) play a crucial role in physiological and pathological matrix turnover. This study aimed to determine the occurrence of MMP and TIMP in lung cancer patients with malignant pleural effusions (CA).
Methods:
MMP-1, MMP-2, MMP-3, MMP-8, MMP-9, TIMP-1, and IMP-2 oncentrations were determined by ELISA and zymography in pleural effusions and plasma of 31 CA and 14 congestive heart failure (CHF) patients and in plasma of 18 healthy controls (CON).
Results:
MMP-2, TIMP-1, and TIMP-2 ELISA-concentrations were increased in CA pleural fluid vs. CA plasma (p < 0.005, p < 0.005, p < 0.05), in contrast to MMP-9 being higher in plasma (p < 0.005). Pleural fluid MMP-1 and MMP-8 were increased in CA vs. CHF (p < 0.05, p < 0.005). MMP and TIMP plasma concentrations were not different in CA vs. CHF, but MMP-9, TIMP-1, and TIMP-2 were increased vs. CON (p < 0.005, each). Gelatine zymography MMP-9/MMP-2 ratios were increased in CA plasma vs. effusion fluid (p < 0.005), in CA vs. CHF plasma, CA vs. CHF effusions (p < 0.005 each), and in CA vs. CON plasma (p < 0.05).
Conclusions:
MMP-2, TIMP-1, and TIMP-2 accumulate in the pleural compartment in CA and CHF, probably reflecting an unspecific pleural reaction. MMP-1 and MMP-8 are increased in cellular rich CA pleural effusions only. The determination of MMP-9/MMP-2 ratios in pleural fluid may contribute to differentiate CHF from CA effusions.
Insights
Matrix metalloproteinases (MMP) and tissue inhibitors of metalloproteinases (TIMP) accumulate in the pleural compartment in lung cancer and heart failure. The MMP-9/MMP-2 ratio in pleural fluid may help differentiate lung cancer from heart failure effusions.
Area of Science:
- Biochemistry of extracellular matrix turnover.
- Oncology and cardiovascular disease research.
Context:
- Matrix metalloproteinases (MMP) and tissue inhibitors of metalloproteinases (TIMP) are key regulators of tissue remodeling.
- Malignant pleural effusions (CA) and congestive heart failure (CHF) involve complex pleural space dynamics.
Purpose:
- To investigate the concentrations and ratios of specific MMPs and TIMPs in pleural effusions and plasma.
- To assess the diagnostic potential of these biomarkers in differentiating lung cancer from CHF.
Summary:
- MMP-2, TIMP-1, and TIMP-2 were elevated in the pleural fluid of both CA and CHF patients.
- MMP-1 and MMP-8 were specifically increased in CA pleural effusions.
- Elevated MMP-9/MMP-2 ratios in pleural fluid were observed in CA compared to CHF and controls.
Impact:
- Findings suggest MMP accumulation in pleural effusions is partly an unspecific reaction.
- MMP-1 and MMP-8 may serve as potential indicators for lung cancer in pleural effusions.
- The MMP-9/MMP-2 ratio shows promise as a biomarker for distinguishing malignant pleural effusions from those caused by heart failure.
Related Concept Videos
01:28Pleural Effusion II: Symptoms and Management
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
01:23Role of Matrix Metalloproteases in Degradation of ECM
A...
01:25Pleural Effusion I: Introduction
There are two main types of pleural effusion: transudative and exudative. They are differentiated using Light's criteria,...